Literature DB >> 35588749

Lars Palmowski, Michael Adamzik, Tim Rahmel.   

Abstract

The new Surviving Sepsis Campaign (SSC) guideline was substantially revised in 2021. These updated recommendations are intended to guide intensivists in providing adequate care to adult patients with sepsis or septic shock. In particular, the current SSC guideline emphasizes early recognition and stringent management in the first hours after the onset of sepsis. In particular, the implementation of acute interventions should help to improve the chances of survival of sepsis patients.This article summarizes the most important recommendations for acute therapy and presents them as a comparative overview to the previous SSC guideline and the German S3 guideline. This should allow the reader to adopt the knowledge from the new guideline into clinical practice as quickly as possible in order to improve the quality of treatment of patients with sepsis or septic shock. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35588749     DOI: 10.1055/a-1783-7212

Source DB:  PubMed          Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther        ISSN: 0939-2661            Impact factor:   0.698


  2 in total

1.  Study protocol of REpeat versus SIngle ShoT Antibiotic prophylaxis in major Abdominal Surgery (RESISTAAS I): a prospective observational study of antibiotic prophylaxis practice for patients undergoing major abdominal surgery.

Authors:  Anastasia Murtha-Lemekhova; Juri Fuchs; Miriam Teroerde; Heike Rau; Otto R Frey; Daniel Hornuss; Adrian Billeter; Rosa Klotz; Ute Chiriac; Jan Larmann; Markus A Weigand; Pascal Probst; Katrin Hoffmann
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

2.  The Distinctive Activation of Toll-Like Receptor 4 in Human Samples with Sepsis.

Authors:  Patrick Thon; Katharina Rump; Annika Knorr; Birte Dyck; Dominik Ziehe; Matthias Unterberg; Hartmuth Nowak; Lars Bergmann; Alexander Wolf; Maha Bazzi; Jennifer Orlowski; Marcus Peters; Alexander Zarbock; Thorsten Brenner; Michael Adamzik; Tim Rahmel; Björn Koos
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.